Travere Therapeutics, Inc.
TVTX
$17.92
$0.130.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 111.49% | 97.54% | 65.98% | 69.56% | 68.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 111.49% | 97.54% | 65.98% | 69.56% | 68.08% |
| Cost of Revenue | -9.77% | 1.26% | 0.48% | -13.86% | -17.00% |
| Gross Profit | 2,894.11% | 415.85% | 152.81% | 138.71% | 93.64% |
| SG&A Expenses | 17.66% | 13.41% | 9.30% | -3.22% | -5.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.90% | 8.04% | 4.87% | -8.29% | -11.00% |
| Operating Income | 81.13% | 42.15% | 28.37% | 39.49% | 35.50% |
| Income Before Tax | 81.69% | 69.66% | 31.84% | 38.54% | 31.71% |
| Income Tax Expenses | -76.47% | -79.58% | -205.88% | -800.00% | 30.77% |
| Earnings from Continuing Operations | 81.69% | 69.68% | 31.97% | 38.65% | 31.67% |
| Earnings from Discontinued Operations | -- | -- | 100.25% | -100.02% | -104.64% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 81.88% | 69.70% | 33.17% | -136.36% | 17.78% |
| EBIT | 81.13% | 42.15% | 28.37% | 39.49% | 35.50% |
| EBITDA | 102.41% | 53.25% | 35.59% | 44.78% | 39.03% |
| EPS Basic | 84.22% | 73.55% | 38.50% | -135.67% | 19.37% |
| Normalized Basic EPS | 83.90% | 48.86% | 29.70% | 39.85% | 33.65% |
| EPS Diluted | 84.22% | 73.55% | 38.50% | -135.67% | 19.37% |
| Normalized Diluted EPS | 83.90% | 48.86% | 29.70% | 39.85% | 33.65% |
| Average Basic Shares Outstanding | 14.77% | 14.54% | 8.67% | 1.93% | 1.97% |
| Average Diluted Shares Outstanding | 14.77% | 14.54% | 8.67% | 1.93% | 1.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |